X

Trial Profile

Phase 1/1b study of PUR-3100

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 05 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dihydroergotamine mesilate (Primary)
Indications Migraine
Focus Adverse reactions; Pharmacokinetics; Proof of concept
Sponsors Pulmatrix

Most Recent Events

29 Mar 2022 According to a Pulmatrix media release, This study will form the basis for a US IND.
29 Mar 2022 According to a Pulmatrix media release, the company anticipates initiating patient dosing Australia in Q3 2022, with top-line data anticipated in Q4 2022.
10 Nov 2021 According to a Pulmatrix media release, the company expects to submit the IND in Q1 2022 and initiate the Phase 1 study in Q2 2022 with top line data expected in Q3 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com